A recent SciTechDaily article discussed a promising new study out of the University of Michigan that could change the way we treat lymphoma. The oral drug zanubrutinib was used to combat a specific type of slow-growing cancer known as marginal zone lymphoma. Results showed that the drug shrank cancer in 80% of the 20 subjects, with a fifth of them going into complete remission.
